Gilead's 4-drug combo shows early promise against hepatitis C

03/8/2011 | Bloomberg

A four-drug combination from Gilead Sciences showed promise during an early-stage trial in eliminating hepatitis C virus, RBC Capital Markets analysts said. The result supports an ongoing Phase II trial of the drug, which consists of Gilead's compounds GS-9256 and GS-9190 plus standard treatments ribavirin and pegylated interferon.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA